User profiles for Nicola Silvestris
 | prof. Nicola Silvestris - Full Professor in Medical OncologyMedical Oncology Unit, Department of Human Pathology "G. Barresi", University of Messina … Verified email at unime.it Cited by 11547 |
Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the …
…, S Vitello, S Cinieri, S Mosconi, N Silvestris… - The Lancet …, 2020 - thelancet.com
Background The triplet FOLFOXIRI (fluorouracil, leucovorin, oxaliplatin, and irinotecan) plus
bevacizumab showed improved outcomes for patients with metastatic colorectal cancer, …
bevacizumab showed improved outcomes for patients with metastatic colorectal cancer, …
Prospective evaluation of major vascular events in patients with nonsmall cell lung carcinoma treated with cisplatin and gemcitabine
…, O Garrone, V Dongiovanni, N Silvestris… - … Journal of the …, 2005 - Wiley Online Library
BACKGROUND Cancer and cisplatin‐based chemotherapy both are well recognized risk
factors for coagulation disorders and thrombosis. However, vascular events (VEs) seldom are …
factors for coagulation disorders and thrombosis. However, vascular events (VEs) seldom are …
[HTML][HTML] Liquid biopsy and tumor heterogeneity in metastatic solid tumors: the potentiality of blood samples
…, F Pantano, E Dell'Aquila, C Anesi, N Silvestris… - Journal of Experimental …, 2020 - Springer
In a large number of cancer types, treatment selection depends on the presence of specific
tumor biomarkers. Due to the dynamic nature of cancer, very often these predictive …
tumor biomarkers. Due to the dynamic nature of cancer, very often these predictive …
[HTML][HTML] Current approaches for combination therapy of cancer: the role of immunogenic cell death
…, A Derakhshani, A Argentiero, N Silvestris… - Cancers, 2020 - mdpi.com
Cell death resistance is a key feature of tumor cells. One of the main anticancer therapies is
increasing the susceptibility of cells to death. Cancer cells have developed a capability of …
increasing the susceptibility of cells to death. Cancer cells have developed a capability of …
[HTML][HTML] Plasma-activated medium triggers cell death and the presentation of immune activating danger signals in melanoma and pancreatic cancer cells
…, R Gristina, P Favia, F Fracassi, I Trizio, N Silvestris… - Scientific reports, 2019 - nature.com
Over the past decade, cold atmospheric plasmas have shown promising application in
cancer therapy. The therapeutic use of plasma-activated media is a topic addressed in an …
cancer therapy. The therapeutic use of plasma-activated media is a topic addressed in an …
[HTML][HTML] Hospital admission of cancer patients: avoidable practice or necessary care?
…, A Stella, F Grasso, S Spinazzé, N Silvestris - PloS one, 2015 - journals.plos.org
Background Cancer patients are frequently admitted to hospital due to acute conditions or
refractory symptoms. This occurs through the emergency departments and requires medical …
refractory symptoms. This occurs through the emergency departments and requires medical …
[HTML][HTML] The evolving role of immune checkpoint inhibitors in hepatocellular carcinoma treatment
…, A Buonavoglia, LG Lupo, V De Re, N Silvestris… - Vaccines, 2021 - mdpi.com
Hepatocellular carcinoma (HCC) is one of most common cancers and the fourth leading
cause of death worldwide. Commonly, HCC development occurs in a liver that is severely …
cause of death worldwide. Commonly, HCC development occurs in a liver that is severely …
[HTML][HTML] Neutrophils, crucial, or harmful immune cells involved in coronavirus infection: a bioinformatics study
…, H Bannazadeh Baghi, N Silvestris… - Frontiers in …, 2020 - frontiersin.org
The latest member of the Coronaviridae family, called SARS-CoV-2, causes the Coronavirus
Disease 2019 (COVID-19). The disease has caused a pandemic and is threatening global …
Disease 2019 (COVID-19). The disease has caused a pandemic and is threatening global …
[HTML][HTML] Incidence of patients with bone metastases at diagnosis of solid tumors in adults: a large population-based study
…, J Shen, X Li, R Rengan, N Silvestris… - Annals of …, 2020 - ncbi.nlm.nih.gov
Background Bones are one of the most common metastatic sites for solid malignancies. Bone
metastases can significantly increase mortality and decrease the quality of life of cancer …
metastases can significantly increase mortality and decrease the quality of life of cancer …
Prognostic vs predictive molecular biomarkers in colorectal cancer: is KRAS and BRAF wild type status required for anti-EGFR therapy?
…, G Bronte, D Fanale, L Corsini, N Silvestris… - Cancer treatment …, 2010 - Elsevier
An important molecular target for metastatic CRC treatment is the epidermal growth factor
receptor (EGFR). Many potential biomarkers predictive of response to anti-EGFR monoclonal …
receptor (EGFR). Many potential biomarkers predictive of response to anti-EGFR monoclonal …